LENZ THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
LENZ THERAPEUTICS, INC. (LENZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $5.30 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2022-11-09
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $5.30M, a 231.25% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-06-30 was $4.90M, a 4800.00% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $1.80M, a 1700.00% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-09-30 was $1.60M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2022-09-30 | $5.30M 10-Q · filed 2022-11-09 | $10.20M derived: sum of 2 quarters · filed 2022-11-09 | $12.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $4.90M 10-Q · filed 2022-08-11 | $6.70M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.80M 10-Q · filed 2022-05-12 | ||
| 2021-09-30 | $1.60M 10-Q · filed 2022-11-09 | $1.70M derived: sum of 2 quarters · filed 2022-11-09 | $2.90M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-11 | $1.30M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-12 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |